Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

NCT03743025 on ClinicalTrials.gov · last registry update 2024-05-30

Stopped early, having planned 28 participants. The sponsor logged completion for 2 May 2023. Primary outcome, as filed: Number of Participants With Blood Glucose Levels (BG) > 140 mg/dl During Post Operative Period.

Status: TERMINATED
Phase: P4
Drug: dulaglutide
Trulicity
Sponsor: Emory University
Sponsor type: Other
Enrollment: 28
Started: 2019-03-08
Primary completion: 2023-05-02 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Number of Participants With Blood Glucose Levels (BG) > 140 mg/dl During Post Operative Period

Conditions studied

Stress Hyperglycemia

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.